Readability, Quality, and Timeliness of Patient Online Health Resources for Contact Dermatitis and Patch Testing
- PMID: 34570732
- DOI: 10.1097/DER.0000000000000789
Readability, Quality, and Timeliness of Patient Online Health Resources for Contact Dermatitis and Patch Testing
Abstract
Background: Contact dermatitis (CD) causes significant impact on patient quality of life. It is the most common occupational skin disease, accounting for more than US $1 billion of medical costs. Patch testing (PT) is the criterion standard for diagnosis of allergic CD. Patients are increasingly using the Internet to obtain health information; however, the readability, quality, and timeliness of online health resources for CD and PT are unknown.
Objective: The objective was to determine the readability, quality, and timeliness of the most frequently accessed patient online health resources for CD and PT.
Methods: A Google search was performed on March 20, 2021, using the terms "contact dermatitis," "contact eczema," "patch testing," and "patch test." Websites were evaluated using several well-validated tools/criteria.
Results: Contact dermatitis and PT websites had only 2 of the 48 websites combined that met the recommended sixth-grade reading level for patients, with the majority characterized as "very poor" to "fair" quality. There was no correlation found between quality and readability of the CD and PT websites.
Conclusions: There is a need for improvement of online CD and PT health resources. Dermatologists should take the lead to vet websites and enhance online resources to improve patient care.
Copyright © 2021 American Contact Dermatitis Society. All Rights Reserved.
Conflict of interest statement
V.Y.S. is on the board of directors for the Hidradenitis Suppurativa Foundation (HSF); is a stock shareholder of Learn Health; and has served as an advisor, investigator, and/or speaker for Sanofi Genzyme, Regeneron, AbbVie, Burt's Bees, Dermira, Eli Lilly, Novartis, Pfizer, Galderma, Leo Pharma, SUN Pharma, Menlo Therapeutics, TARGET-DERM, Kiniksa, GpSkin, and Skin Actives Scientific. J.L.H. is on the board of directors for the HSF and has served as an advisor for Novartis and speaker for AbbVie. The other authors have no funding or conflicts of interest to declare.
References
-
- Alinaghi F, Bennike NH, Egeberg A, et al. Prevalence of contact allergy in the general population: a systematic review and meta-analysis. Contact Dermatitis 2019;80(2):77–85. doi:10.1111/cod.13119.
-
- Brar KK. A review of contact dermatitis. Ann Allergy Asthma Immunol 2021;126(1):32–39. doi:10.1016/j.anai.2020.10.003.
-
- Kadyk DL, McCarter K, Achen F, et al. Quality of life in patients with allergic contact dermatitis. J Am Acad Dermatol 2003;49(6):1037–1048. doi:10.1016/S0190-9622(03)02112-1.
-
- Zack B, Arrandale VH, Holness DL. Preventing occupational skin disease: a review of training programs. Dermatitis 2017;28(3):169–182. doi:10.1097/DER.0000000000000278.
-
- Fonacier L, Noor I. Contact dermatitis and patch testing for the allergist. Ann Allergy Asthma Immunol 2018;120(6):592–598. doi:10.1016/j.anai.2018.03.003.
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous
